Viking Therapeutics, Inc.’s VK2735 trial results disappointed, yet long-term potential in the obesity market makes the stock dip a buy. Click for my VKTX update.
Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success
view original post